ACAD
34.83
+0.38
+1.10%
AEMD
3.35
-0.4
-10.67%
APRI
2.25
-0.04
-1.75%
ARNA
1.46
+0.01
+0.69%
ATEC
2.19
+0.12
+5.80%
CNAT
4.82
+0.23
+5.01%
CRXM
0.2
0.00
0.00%
CYTX
1.65
+0.01
+0.61%
DXCM
82.62
+6.54
+8.60%
GNMK
13.4
+0.26
+1.98%
HALO
13.53
+0.07
+0.52%
ILMN
170.58
+2.89
+1.72%
INNV
0.11
0.00
+4.08%
INO
6.05
+0.1
+1.68%
ISCO
1.78
+0.13
+7.88%
ISIS
57.56
0.00
0.00%
LGND
104.78
+0.99
+0.95%
LPTN
2.93
-0.08
-2.66%
MBVX
2.27
-0.24
-9.56%
MEIP
1.54
-0.03
-1.91%
MNOV
5.87
+0.06
+1.03%
MRTX
5.15
+0.05
+0.98%
MSTX
0.114
+0.007
+6.542%
NBIX
41.98
+0.48
+1.16%
NUVA
74.85
+0.56
+0.75%
ONCS
1.27
+0.02
+1.60%
ONVO
3.03
+0.02
+0.66%
OREX
3.98
-0.02
-0.50%
OTIC
12.85
-0.25
-1.91%
QDEL
21.84
+0.17
+0.76%
RCPT
231.96
0.00
0.00%
RGLS
1.4
+0.15
+12.00%
RMD
71.57
+0.26
+0.36%
SPHS
2.87
+0.29
+11.24%
SRNE
4.1
-0.1
-2.38%
TROV
1
-0.15
-13.04%
VICL
2.15
+0.02
+0.94%
VOLC
18
0.00
0.00%
ZGNX
10.45
+0.05
+0.48%
ACAD
34.83
+0.38
+1.10%
AEMD
3.35
-0.4
-10.67%
APRI
2.25
-0.04
-1.75%
ARNA
1.46
+0.01
+0.69%
ATEC
2.19
+0.12
+5.80%
CNAT
4.82
+0.23
+5.01%
CRXM
0.2
0.00
0.00%
CYTX
1.65
+0.01
+0.61%
DXCM
82.62
+6.54
+8.60%
GNMK
13.4
+0.26
+1.98%
HALO
13.53
+0.07
+0.52%
ILMN
170.58
+2.89
+1.72%
INNV
0.11
0.00
+4.08%
INO
6.05
+0.1
+1.68%
ISCO
1.78
+0.13
+7.88%
ISIS
57.56
0.00
0.00%
LGND
104.78
+0.99
+0.95%
LPTN
2.93
-0.08
-2.66%
MBVX
2.27
-0.24
-9.56%
MEIP
1.54
-0.03
-1.91%
MNOV
5.87
+0.06
+1.03%
MRTX
5.15
+0.05
+0.98%
MSTX
0.114
+0.007
+6.542%
NBIX
41.98
+0.48
+1.16%
NUVA
74.85
+0.56
+0.75%
ONCS
1.27
+0.02
+1.60%
ONVO
3.03
+0.02
+0.66%
OREX
3.98
-0.02
-0.50%
OTIC
12.85
-0.25
-1.91%
QDEL
21.84
+0.17
+0.76%
RCPT
231.96
0.00
0.00%
RGLS
1.4
+0.15
+12.00%
RMD
71.57
+0.26
+0.36%
SPHS
2.87
+0.29
+11.24%
SRNE
4.1
-0.1
-2.38%
TROV
1
-0.15
-13.04%
VICL
2.15
+0.02
+0.94%
VOLC
18
0.00
0.00%
ZGNX
10.45
+0.05
+0.48%
Home » Archive by Category

Xconomy

AnaptysBio Adds More Shares, Raises $75M in Stock Market Debut

January 26, 2017 – 9:59 am

AnaptysBio is the first U.S. biotech company to go public this year, raising $75 million in an IPO intended to finance development of antibody-based drugs for inflammatory disorders. The San…

[[Click headline to continue reading.]]

Just Four Months After Series A, Delinia Sells to Celgene For $300M

January 26, 2017 – 5:35 am

It didn’t take long for startup Delinia to entice a big drug developer: Just over four months after emerging from stealth and raising a Series A round, the company, developing drugs for a range of…

[[Click headline to continue reading.]]

Inspired by NFL Teammate, Aethlon Seeks Diagnostic for Brain Injuries

January 25, 2017 – 6:56 am

Just as the NFL marketing machine is stoking the build-up to Super Bowl LI, a San Diego diagnostic company headed by a former Denver Broncos player has unveiled plans for a new clinical study of…

[[Click headline to continue reading.]]

Anthem Caps Coverage Of Biogen Spine Drug Despite Wide FDA Approval

January 24, 2017 – 10:50 am

One of the nation’s major health insurers has placed limitations on access to the first-ever approved drug for the rare spinal muscular atrophy, validating patient fears that the high price tag of…

[[Click headline to continue reading.]]

Report: Biotech VCs Perpetuate Boardroom Gender Gap

January 24, 2017 – 6:39 am

If power in the business world is centered in the boardroom, women in biotech have a long way to go to get their fair share—and the venture community deserves much of the blame. That’s…

[[Click headline to continue reading.]]

Ex-FDA Commish Califf Gives Props to Patient Groups—With Caveats

January 23, 2017 – 11:40 am

The nation’s former Food and Drug Administration commissioner Robert Califf, appearing for the first time since he resigned last week, told a Silicon Valley crowd this morning that the FDA will…

[[Click headline to continue reading.]]

Bio Roundup: Tom Price, Patient Conflicts, Orphan Games & More

January 20, 2017 – 4:18 am

The new president of the United States, Donald Trump, is being sworn in today amid a storm of questions about the plans that he, and those who might work for him, have in store for American…

[[Click headline to continue reading.]]

Cytori Buys San Antonio-based Azaya’s Drug Delivery Tech for Stock

January 19, 2017 – 1:38 pm

San Antonio — Cytori Therapeutics, a San Diego, CA-based developer of drugs that use patients’ own fat tissues to make cellular therapies, is buying the assets of San Antonio-based Azaya…

[[Click headline to continue reading.]]

Dems Grill HHS Nominee Price About Trump Comments, Stock Holdings

January 18, 2017 – 2:03 pm

[Note: This report was co-authored by deputy biotech editor Ben Fidler.] Tom Price, the man who could oversee an overhaul of the U.S. healthcare system, answered often pointed questions this morning…

[[Click headline to continue reading.]]

Biotech Roundup: JPM Deals, Gender Diversity, PCSK9 Battle & More

January 13, 2017 – 6:07 am

[Corrected, 1/14/16, see below] This past week, the biopharma industry made its annual January pilgrimage to San Francisco for the J.P. Morgan Healthcare Conference. 2016 was a whirlwind year in…

[[Click headline to continue reading.]]